IRX5183 / Io Therap - LARVOL DELTA

Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (clinicaltrials.gov) - P1/2; N=13; Terminated; Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; N=40 ➔ 13; Trial completion date: Dec 2021 ➔ Aug 2018; Recruiting ➔ Terminated; Trial primary completion date: Dec 2020 ➔ Aug 2018; Study drug supply expired and could not be renewed.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination